No connection

Search Results

ABBV vs AHG

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AHG
Akso Health Group
BEARISH
Price
$2.50
Market Cap
$2.14B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
AHG
--
Forward P/E
ABBV
15.42
AHG
--
P/B Ratio
ABBV
-146.66
AHG
10.82
P/S Ratio
ABBV
6.5
AHG
144.3
EV/EBITDA
ABBV
15.27
AHG
-4387.63

Profitability

Gross Margin
ABBV
71.46%
AHG
1.0%
Operating Margin
ABBV
35.5%
AHG
-20.54%
Profit Margin
ABBV
4.0%
AHG
0.0%
ROE
ABBV
137.96%
AHG
-68.29%
ROA
ABBV
9.59%
AHG
-1.42%

Growth

Revenue Growth
ABBV
9.1%
AHG
0.9%
Earnings Growth
ABBV
-88.7%
AHG
--

Financial Health

Debt/Equity
ABBV
--
AHG
0.01
Current Ratio
ABBV
0.72
AHG
1.53
Quick Ratio
ABBV
0.47
AHG
1.19

Dividends

Dividend Yield
ABBV
3.05%
AHG
--
Payout Ratio
ABBV
490.15%
AHG
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AHG BEARISH

AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.

Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns

Compare Another Pair

ABBV vs AHG: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Akso Health Group (AHG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile